Total Payments
$6,603
2024 Payments
$17.13
Companies
5
Transactions
17
Medicare Patients
1,179
Medicare Billing
$224,305
Payment Breakdown by Category
Other$6,000 (90.9%)
Food & Beverage$556.86 (8.4%)
Travel$40.61 (0.6%)
Education$5.10 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000 | 3 | 90.9% |
| Food and Beverage | $556.86 | 10 | 8.4% |
| Travel and Lodging | $40.61 | 3 | 0.6% |
| Education | $5.10 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Theravance Biopharma Inc. | $6,395 | 12 | $0 (2017) |
| Bard Peripheral Vascular, Inc. | $140.33 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $30.08 | 2 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $22.18 | 1 | $0 (2021) |
| Allergan Inc. | $14.93 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.13 | 1 | Gilead Sciences, Inc. ($17.13) |
| 2021 | $22.18 | 1 | Paratek Pharmaceuticals, Inc. ($22.18) |
| 2019 | $12.95 | 1 | Gilead Sciences, Inc. ($12.95) |
| 2018 | $140.33 | 1 | Bard Peripheral Vascular, Inc. ($140.33) |
| 2017 | $6,410 | 13 | Theravance Biopharma Inc. ($6,395) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.13 | General |
| 06/02/2021 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: ANTIBIOTIC | ||||||
| 04/24/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.95 | General |
| 04/12/2018 | Bard Peripheral Vascular, Inc. | ENCOR (Device) | Food and Beverage | In-kind items and services | $140.33 | General |
| Category: VASCULAR | ||||||
| 12/15/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Infectious Disease | ||||||
| 10/05/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Education | In-kind items and services | $5.10 | General |
| Category: Infectious Disease | ||||||
| 07/19/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Infectious Disease | ||||||
| 07/19/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $107.71 | General |
| Category: Infectious Disease | ||||||
| 07/19/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Travel and Lodging | Cash or cash equivalent | $9.20 | General |
| Category: Infectious Disease | ||||||
| 06/29/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/31/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Infectious Disease | ||||||
| 05/31/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $100.54 | General |
| Category: Infectious Disease | ||||||
| 05/31/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Travel and Lodging | Cash or cash equivalent | $8.03 | General |
| Category: Infectious Disease | ||||||
| 03/09/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $3.80 | General |
| Category: Infectious Disease | ||||||
| 03/02/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Infectious Disease | ||||||
| 03/02/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Travel and Lodging | Cash or cash equivalent | $23.38 | General |
| Category: Infectious Disease | ||||||
| 02/16/2017 | Theravance Biopharma Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $124.87 | General |
| Category: Infectious Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 215 | 520 | $122,440 | $42,799 |
| 2022 | 5 | 199 | 381 | $67,865 | $26,773 |
| 2021 | 5 | 288 | 614 | $107,358 | $43,941 |
| 2020 | 8 | 477 | 1,482 | $302,018 | $110,792 |
Total Patients
1,179
Total Services
2,997
Medicare Billing
$224,305
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96521 | Refilling and maintenance of portable pump | Office | 2023 | 13 | 162 | $60,750 | $15,669 | 25.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 79 | 174 | $24,360 | $10,549 | 43.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 67 | 97 | $20,370 | $8,865 | 43.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 46 | $8,970 | $4,545 | 50.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $5,130 | $1,817 | 35.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 22 | $2,860 | $1,355 | 47.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 79 | 225 | $31,500 | $12,649 | 40.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 72 | 107 | $22,470 | $8,734 | 38.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $6,920 | $2,580 | 37.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 19 | $5,285 | $1,937 | 36.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 13 | $1,690 | $873.00 | 51.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 131 | 383 | $52,544 | $21,895 | 41.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 87 | 152 | $31,456 | $12,440 | 39.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 34 | 38 | $15,104 | $6,062 | 40.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 20 | 21 | $5,670 | $2,283 | 40.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 20 | $2,584 | $1,261 | 48.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 161 | 533 | $72,488 | $30,995 | 42.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 128 | 302 | $62,212 | $25,457 | 40.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 20 | 317 | $71,325 | $17,957 | 25.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 65 | 68 | $26,996 | $11,108 | 41.1% |
| 96521 | Refilling and maintenance of portable pump | Office | 2020 | 11 | 97 | $36,375 | $11,048 | 30.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 20 | 78 | $15,054 | $6,765 | 44.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 44 | 45 | $12,150 | $5,040 | 41.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 28 | 42 | $5,418 | $2,422 | 44.7% |
About Dr. Aamina Akhtar, MD
Dr. Aamina Akhtar, MD is a Infectious Disease healthcare provider based in St. Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124095831.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aamina Akhtar, MD has received a total of $6,603 in payments from pharmaceutical and medical device companies, with $17.13 received in 2024. These payments were reported across 17 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($6,000).
As a Medicare-enrolled provider, Akhtar has provided services to 1,179 Medicare beneficiaries, totaling 2,997 services with total Medicare billing of $224,305. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location St. Louis, MO
- Active Since 03/01/2006
- Last Updated 04/11/2017
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1124095831
Products in Payments
- VIBATIV (Drug) $6,395
- ENCOR (Device) $140.33
- NUZYRA (Drug) $22.18
- AVYCAZ (Drug) $14.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.